ESSDAI and ESSPRI baseline values in real-life cohorts and clinical trials
| ESSDAI at inclusion | ESSPRI at inclusion | ||||
|---|---|---|---|---|---|
| ≥4 | ≥5 | ≥6 | ≥5 | ≥6 | |
| Real-life cohorts | |||||
| EULAR3 (n=395) | 256/385 (66.5%) | 236/385 (61.3%) | 207/385 (53.8%) | 267/392 (68.1%) | 214/392 (54.69%) |
| ASSESS6 (n=395) | 167/383 (43.6%) | 140/383 (36.6%) | 124/383 (32.4%) | 219/356 (61.5%) | 156/356 (43.8%) |
| Clinical trials | |||||
| TRIPPS11 (n=103) | NA | NA | NA | 98/103 (95.2%) | 79/103 (76.7%) |
| RTX trial (the Netherlands)14 (n=30) | 28 (93.3%) | 23 (76.7%) | 22 (73.3%) | NA | NA |
| BELISS16 (n=30) | 21 (70.0%) | 18 (60.0%) | 18 (60.0%) | 28 (93.3%) | 21 (70.0%) |
| ASAP15 (n=15) | 14 (93.3%) | 14 (93.3%) | 14 (93.3%) | 12/14 (85.7%) | 12/14 (85.7%) |
| TEARS12 (n=122) | 108 (88.5%) | 93 (76.2%) | 89 (73.0%) | 97/122 (79.5%) | 76/122 (62.3%) |
| JOQUER13 (n=120) | 47/119 (39.5%) | 38/119 (31.9%) | 32/119 (26.9%) | 83/117 (70.9%) | 64/117 (54.7%) |
ASSESS, Assessment of Systemic Signs and Evolution of SS; EULAR, European League Against Rheumatism; ESSDAI, EULAR Sjögren's syndrome disease activity index; ESSPRI, EULAR Sjögren's syndrome patient-reported index; NA, not available.